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Which bronchodilator in COPD?
There have been few developments in the pharmacotherapy of chronic obstructive 
pulmonary disease (COPD) that have been so eagerly awaited as that of a long acting 
anticholinergic compound. For the ﬁ  rst time there was a treatment available which 
was designed with COPD speciﬁ  cally in mind. This was not an asthma treatment 
that had been tried in COPD with more hope than expectation. Tiotropium has now 
been available in Europe for 5 years and in the US for 3. Has this drug lived up to the 
expectations with which it was greeted?
In this edition of the International Journal of COPD we publish two papers which 
review the data for the efﬁ  cacy of Tiotropium and compare its effects with long act-
ing beta-agonists. The analysis of Rice and colleagues (2007) clearly demonstrates 
that Tiotropium is an effective bronchodilator in COPD patients. Peak and trough 
forced expiratory volume in one second (FEV1) measurements were signiﬁ  cantly 
increased and these changes were sustained throughout the study periods (up to 1 
year). Exacerbations of COPD are of great importance to patients, medical staff and 
medical funding bodies. The ﬁ  nding of a reduction in exacerbation rate and hospital 
admissions is thus of signiﬁ  cance.
Hodder and colleagues (2007) compare in a post-hoc analysis the efﬁ  cacy of tiotro-
pium and salmeterol in patients who may or may not be taking inhaled corticosteroids 
in two studies over a six month period. The ﬁ  ndings do not help us understand the role 
of inhaled steroids in COPD but do demonstrate that both salmeterol and tiotropium are 
effective notwithstanding the steroid status of the subjects. The patients taking steroids 
were found to have worse lung function and breathlessness at enrolment. The reduced 
responses to therapy, particularly the exacerbation rate, may reﬂ  ect this. However it 
was clear that a physician’s decision to place a patient on inhaled steroids is based on 
more than a slightly worse FEV1 or slightly more breathlessness.
There is still a need in such studies to demonstrate clinically meaningful beneﬁ  t. 
Lung function changes are straightforward to measure but do they translate into 
improvements in quality of life and exercise tolerance? The data presented thus far 
is relatively weak in this area. Moreover there is a question or the generalisability of 
the data presented. For reasonable reasons patients with signiﬁ  cant co morbidities 
are excluded (especially cardiovascular disease) which is never the case in real life. 
What effect the inclusion of such patients would have on trial results is uncertain; such 
patients are more symptomatic, have more exacerbations and thus may decline faster. 
On the other hand these patients may respond better to an effective therapy.
The other pressing need that these papers demonstrate is that we need an under-
standing of disease phenotype (Celli and Roger 2006). Of greater clinical signiﬁ  cance 
is that we do not understand the phenotypes of potential responders to pharmacological 
therapies. Who will respond to anticholinergics, who to beta agonists? Who should 
receive inhaled corticosteroids? The pragmatic approach is to use both or all in com-
bination in severe disease as each therapy has an entirely different mechanism of 
action which may be complementary. Each does contribute something to a reduction 
in exacerbation rate, an improvement in lung function and perhaps an improvement in 
a patient’s life. The recent study by Aaron and colleagues (2007) shows some beneﬁ  ts 
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in terms of lung function and symptoms, but the study was 
underpowered to evaluate its primary endpoint of exacerba-
tion rates. Further studies to deﬁ  ne properly the beneﬁ  ts of 
such a combined therapy approach are needed. The results 
of the now complete UPLIFT study are thus eagerly awaited 
(Decramer et al 2004).
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